VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

Keyphrases

• Myeloid Cells 100%
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 100%
• Immune Suppression 100%
• Tumor Microenvironment 100%
• Immune Therapy 33%
• Immune Checkpoint Blockade 33%
• Mechanistic Insight 16%
• Tumor Immunity 16%
• T Cell Activation 16%
• Therapeutic Effect 16%
• Vascular Endothelial Growth Factor 16%
• Angiogenesis 16%
• Cancer Treatment 16%
• Patients with Cancer 16%
• Antiangiogenic 16%
• Tumor-bearing Animals 16%
• Anti-VEGF Therapy 16%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 16%
• Programmed Death-ligand 1 (PD-L1) 16%
• Hereafter 16%
• VEGF Expression 16%
• Cancer Hallmarks 16%
• VEGF Inhibition 16%
• Tumor-associated Myeloid Cells 16%
• VEGF Blockade 16%

Medicine and Dentistry

• Immunosuppressive Treatment 100%
• Vasculotropin 100%
• Myeloid Cell 100%
• Tumor Microenvironment 100%
• Immunotherapy 28%
• Neoplasm 28%
• Immunosuppressive Drug 28%
• Immune Checkpoint Blockade 28%
• Malignant Neoplasm 14%
• Clinical Study 14%
• T Cell Activation 14%
• Tumor Immunity 14%
• Therapy Effect 14%
• Angiogenesis 14%
• Cancer Therapy 14%
• Antiangiogenic 14%
• Vasculotropin A 14%
• Programmed Death 1 Ligand 1 14%

Immunology and Microbiology

• Myeloid 100%
• Vasculotropin 100%
• Immunosuppressive Drug 28%
• Immunotherapy 28%
• Immune Checkpoint Blockade 28%
• T Cell Activation 14%
• Angiogenesis 14%
• Tumor Immunity 14%
• Vasculotropin A 14%
• Programmed Death 1 Ligand 1 14%